Autopsy report · NCT01671956
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
Cause of deathFunding or business
“Sponsor Decision.”
Life of this trial
- Registered 3 years before it started.
- Ran for about 3 years 3 months before it stopped.
- 32 participants enrolled.
- Results were posted on the registry 7 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Ulcerative Colitis, Active Moderate; Ulcerative Colitis, Active Severe
- Interventions
- Bertilimumab; Placebo
- Participants
- 32
- Sites
- 6
- Countries
- Israel
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.